Modeling Public Health Campaigns for Sexually Transmitted Infections via Optimal and Feedback Control

- ³ Ariel Camacho · Fernando Saldaña · Ignacio
- 4 Barradas · Silvia Jerez

6 Received: date / Accepted: date

7 Abstract Control of sexually transmitted infections (STIs) poses important chal-

lenges to public health authorities. Obstacles for STIs control include low priority

in public health programs and disease transmission mechanisms. This work uses a
 compartmental pair model to explore different public health strategies on the evolu-

compartmental pair model to explore different public health strategies on the evolu tion of STIs. Optimal and feedback control are used to model realistic strategies for

reducing the prevalence of these infections. Feedback control is proposed to model

¹³ the reaction of public health authorities relative to an alert level. Optimal control is

¹⁴ used to model optimization of available resources for implementing strategies. Nu-

¹⁵ merical simulations are performed using trichomoniasis, gonorrhea, chlamydia and

¹⁶ human papillomavirus (HPV) as study cases. HPV is non-curable and it is analyzed

¹⁷ only under transmission control such as condom promotion campaigns. Trichomo-

¹⁸ niasis, gonorrhea, and chlamydia are curable STIs that are modeled here addition-

ally under treatment control. Increased cost-effectiveness ratio (ICER) is employed
 as a criterion to measure control strategies performance. The features and draw-

as a criterion to measure control strategies performance. The features and draw backs of control strategies under the pair formation process are discussed.

Keywords Pair model · Optimal control · Feedback control · Sexually transmitted
 infections.

24 1 Introduction

²⁵ Sexually transmitted infections (STIs) constitute a serious public health issue. It has

²⁶ been estimated that the annual direct cost in the US for treating these infections is

²⁷ approximately \$ 16 billion (Owusu-Edusei et al., 2013). Implementation of disease

²⁸ control public health strategies is a complex process. Multiple factors are involved,

²⁹ such as available resources as well as geographical and political considerations that

³⁰ change over time. Thus, designing control strategies and determining optimal re-

³¹ source allocation are not straightforward tasks.

Ariel Camacho · Fernando Saldaña · Ignacio Barradas · Silvia Jerez Centro de Investigación en Matemáticas, Guanajuato, Mexico E-mail: jose.camacho@cimat.mx

Although there are over 30 important bacterial, viral and parasitic diseases 1 that can be transmitted by sexual contact (Gerbase et al., 1998), we focus on four 2 of the most common and problematic STIs: trichomoniasis, gonorrhea, chlamyз dia, and human papillomavirus (HPV) infection. The first three of these infections are curable. In many cases, these infections may go undetected because often they are asymptomatic. Thus, they can lead to severe complications such as 6 pelvic inflammatory disease, ectopic pregnancy, infertility, chronic pelvic pain, neonatal death, and severe disability in infants, among others (Newman et al., 8 2015). Since 1995, the World Health Organization (WHO) has generated global 9 estimates for the prevalence of trichomoniasis, gonorrhea, and chlamydia every 10 five years (Newman et al., 2015). Hence, the majority of curable STIs' control poli-11 cies focus on these three infections. Furthermore, according to the Centers for 12 Disease Control and Prevention, HPV is the most common sexually transmitted 13 infection in the United States (CDC, 2013). In addition to its high prevalence, 14 15 HPV infection is the main etiological factor for the development of cervical can-16 cer and therefore constitutes a serious public health issue. Currently, there is no 17 treatment for the virus itself, but there are vaccines to prevent infection by some of the most common HPV types and treatment for HPV-associated diseases, in-18 cluding genital warts and cervical cancer. 19 Despite advances in STI control, the development of effective measures contin-20 ues to challenge public health authorities (Unemo et al., 2017). Moreover, continu-21 ous budget cuts to STI programs pose additional constraints for implementing ef-22 fective control strategies optimally. Therefore, studies addressing infectious disease 23 control to identify optimal strategies for specific health care goals are of growing 24 importance. 25 Mathematical modeling offers a theoretical framework to test hypotheses and 26 predict outcomes related to infectious diseases. Spread predominantly by sexual 27 contacts, STIs usually occur among sexual partners. Several mathematical mod-28 els that study STI dynamics assume that the population is mixed homogeneously, 29 and therefore each sexual contact occurs randomly among individuals (Brauer and 30 Castillo, 2012). For instance, a mathematical model was recently explored to deter-31 mine optimal strategies to control HPV transmission in Malik et al. (2016), screening 32 and vaccination strategies for HPV in an unscreened population are studied in Mil-33 wid et al. (2018), and a syphilis mathematical model is proposed in Gumel et al. 34 (2018). 35 The previously mentioned works, however, do not consider the pair formation process. Mathematical pair models include the number of sexual partnerships as 37 an explicit variable (Kretzschmar and Dietz, 1998; Heijne et al., 2011; Muller and 38 Bauch, 2010). These models confirmed that partnership duration is an important 39 element in STI epidemiology. In fact, excluding partnerships may potentially bias 40

41 the model outcome. For a complete review of pair models, see Kretzshmar and

⁴² Heijne (2017) and the references therein.

Bearing this in mind, in many biological systems questions arise regarding how external forces modify their dynamics. In epidemiological models, input functions are introduced to describe how human efforts (e.g. vaccination) modify the evolution and spread of population diseases. Examples of this approach are Wang (2006) where constant and linear treatment functions are introduced, Zhang and Liu (2008) where a saturated treatment function is considered, and Villaviencio Pulido et al.

⁴⁹ (2017) where an exponential decay treatment function is studied.

As a first attempt to control an STI, the most simple strategy is to apply con-1 stant control efforts (constant control). Constant controls reflect permanent health 2 programs. However, this is not a practical strategy since it does not take into conз sideration the evolution of the disease. One improvement is to place control efforts according to the prevalence levels. If levels are low, efforts would be decreased in order to minimize the use of resources. In this case, the input function will depend 6 on the infected population variable (feedback control). An example of this approach 7 may be found in a previous work (Saldaña and Barradas, 2019). Nevertheless, feed-8 back functions do not consider the number of resources required to implement the 9 corresponding strategies. As a final improvement, we ask that control efforts op-10 timize a predefined objective function (optimal control). This can be posed as an 11 optimal control problem, a modeling framework that has already been used in bi-12 ological models (Lenhart and Workman, 2007; Sharomi and Malik, 2017; Camacho 13 and Jerez, 2019). It is important to stress that in this work "resources" and "costs" 14 15 refer to amounts of economic, human and material resources.

The aim of this work is to discern efficient strategies to control STIs. Here we de-16 scribe trichomoniasis, gonorrhea, chlamydia and HPV infection dynamics as case 17 studies by incorporating parameters from the literature. To this end, we use pair 18 models to consider pair formation processes (Kretzschmar and Dietz, 1998). We 19 also perform a cost-effectiveness analysis using the increased cost-effectivity ratio 20 (ICER) (Okosun et al., 2011; Cape et al., 2013). A feature in our work is that we em-21 ploy the ICER as a way to measure different types of control strategies (constant, 22 feedback and optimal control). 23 The rest of this work is organized as follows. In Section 2 we extend a pair model 24

proposed in Kretzschmar and Dietz (1998) by including two control functions. The 25 first one represents efforts of moving infected people back into the susceptible com-26 partment (treatment) while the second one represents decrement of transmission 27 probability (condom promotion). We find the basic reproduction number \mathcal{R}_0 under 28 constant control functions. Next, in Section 3 we introduce an objective functional 29 that penalizes the presence of infected individuals and the indiscriminate use of 30 the two public health strategies. Then, we pose an optimal control problem and 31 proceed to characterize the optimal solutions. In Section 4 we present numerical re-32 sults corresponding to the four STIs considered in this work under different control 33 strategies. This is accompanied by a brief cost-effectiveness analysis to compare STI 34 control strategies. Finally, in Section 5 we discuss the obtained results in this work 35 and we mention our conclusions. 36

2 Sexually Transmitted Infections Pair Model

³⁸ We consider an epidemic model with non-zero partnership length to study the dy-

³⁹ namics of a curable STI in a population based on Kretzschmar and Dietz (1998).

 $_{40}$ The model is constructed under the Susceptible-Infectious-Susceptible (SIS) frame-

41 work. It includes explicitly the number of people in a partnership as a state variable.

⁴² The total number of single individuals at time t is denoted by X(t) while the total

⁴³ number of pairs of individuals in the population is P(t). Thus, the total population ⁴⁴ size N(t) at time t is N(t) = X(t) + 2P(t). The basic assumptions that govern the

size N(t) at time t is N(t) = X(t) + 2P(t). The basic assumptions that govern the model are the following (Saldaña and Barradas, 2019) (see also Figure 1):




Fig. 1: Schematic representation of the model (1). Single populations are represented by X. Pair populations are represented by P. The states considered here are susceptible 0 and infected 1. For example, P_{01} is the population of pairs with one susceptible and one infected individuals. Arrows denote the flow between compartments.

- 1 (*i*) Susceptible individuals are recruited as singles into the sexually active popula-2 tion at a constant rate ν , and leave the population by dying or ceasing sexual
- ³ activity at a constant rate μ .

4 (*ii*) At a constant rate ρ per unit of time, single individuals form pairs. These are dissolved when the relationships end at a rate σ or when one of the individuals in the pair dies. Since pairs without sexual contact are irrelevant for the spread of the infection, we shall assume that pair formation starts with sexual contact. (*iii*) Transmission can only take place within a pair of a susceptible and an infected

- ⁹ individual. We consider ϕ to be the number of sexual acts per unit of time, and ¹⁰ $h \in (0, 1)$ the transmission probability per contact.
- 11 (*iv*) We extend the model from Kretzschmar and Dietz (1998) by considering the fol-12 lowing. Infected individuals can clear the infection naturally at a rate γ due 13 to the immune response. We assume that the recovery rate γ increases by a 14 time-dependent function u_T (e.g. treatment of infected individuals). Also, we 15 assume that a time-dependent function u_C decreases the transmission probabil-16 ity h (e.g. condom promotion campaigns). Both functions u_T and u_C represent 17 public health authorities' efforts to reduce the prevalence of the infection.

 $X'_{0} = \nu + (\sigma + \mu)(2P_{00} + P_{01}) - (\mu + \rho)X_{0} + (\gamma + u_{T})X_{1},$

¹⁸ Such assumptions lead to the following pair model:

$$\begin{aligned} X_1' &= (\sigma + \mu)(2P_{11} + P_{01}) - (\mu + \rho)X_1 - (\gamma + u_T)X_1, \\ P_{00}' &= \frac{1}{2}\rho\frac{X_0^2}{X} - (\sigma + 2\mu)P_{00} + (\gamma + u_T)P_{01}, \\ P_{01}' &= \rho\left(1 - h(1 - u_C)\right)\frac{X_0X_1}{X} - (\sigma + \phi h(1 - u_C) + 2\mu)P_{01} & (1) \\ &- (\gamma + u_T)P_{01} + 2(\gamma + u_T)P_{11}, \\ P_{11}' &= \frac{1}{2}\rho\frac{X_1^2}{X} + \rho h(1 - u_C)\frac{X_0X_1}{X} + \phi h(1 - u_C)P_{01} - (\sigma + 2\mu)P_{11} \\ &- 2(\gamma + u_T)P_{11}, \end{aligned}$$

Variable	Description
X_0	Single susceptible individuals
X_1	Single infected individuals
P_{00}	Pairs with two susceptible individuals
P_{01}	Pairs with a susceptible and an infected individuals
P_{11}	Pairs with two infected individuals
X	Total number of singles
P	Total number of pairs
u_T	Public health control: treatment of infected individuals
u_C	Public health control: condom promotion

Table 1: State variables for model (1).

Parameter	Description	Units
ν	Recruitment rate	individuals year ⁻¹
μ	Rate of leaving the sexually active population	year ⁻¹
ho	Rate of pair formation	year ⁻¹ year ⁻¹
σ	Separation rate	year ⁻¹
ϕ	Contact frequency within partnerships	year ⁻¹
$1/\gamma$	Infectious period in the absence of treatment	year
h	Transmission probability per contact	dimensionless

Table 2: Interpretation and units for the parameters of model (1).

where the derivative is considered with respect to time, and u_T and u_C are time-

- ² dependent functions. All the parameters are assumed to be non-negative. Tables 1
- ³ and 2 summarize the model variables and parameters.

Before going any further it is important to emphasize the role of the control functions u for $u \in \{u_T, u_C\}$. In our system u(t) represents the impact on the pop-

⁶ ulation due to the efforts (decisions, plans or actions) undertaken by the health care

⁷ system to control the disease at time t. In other words, the functions u_T and u_C

model public health strategies to reduce the prevalence of the STI. In mathematical
 terms, the control functions *u* are non-negative functions that increase the recovery

¹⁰ rate of infected individuals or reduce the transmission probability as a consequence

of the application of public health strategies. As such, any public health care system

¹² has a maximum resource capacity to carry on control strategies. Thus, we assume

¹³ the following:

14

$$0 \le u_T(t) \le M_T, \qquad 0 \le u_C(t) \le M_C \le 1 \tag{2}$$

for all t > 0, where M_T is the maximum increase on the recovery rate γ due to treatment and M_C is the maximum decrease on the transmission probability h due

17 to condom promotion and sexual education campaigns.

18 2.1 Model Reduction

By adding the equations from (1), note that the total population size $N = X_0 + X_1 + 2(P_{00} + P_{01} + P_{11})$ satisfies $N' = -\mu N + \nu$, from which it is easy to see that the set

$$\Omega = \{ (X_0, X_1, P_{00}, P_{01}, P_{11}) \in \mathbb{R}^5_+ \mid X_0 + X_1 + 2(P_{00} + P_{01} + P_{11}) \le \nu/\mu \}$$

¹⁹ is a positively invariant set under model (1), see Appendix A.

Now, let $X = X_0 + X_1$ be the total number of singles and $P = P_{00} + P_{01} + P_{11}$ the total number of pairs. From (1), observe that the dynamics of singles and pairs are described by the the following system of differential equations:

$$X' = \nu + 2(\sigma + \mu)P - (\mu + \rho)X,$$
(3)

$$P' = \frac{1}{2}\rho X - (\sigma + 2\mu)P.$$
 (4)

The partnership dynamics (3)–(4) has a unique equilibrium point (X^*, P^*) : 1

$$X^{*} = \frac{\nu(\sigma + 2\mu)}{\mu(\sigma + 2\mu + \rho)}, \qquad P^{*} = \frac{\nu\rho}{2\mu(\sigma + 2\mu + \rho)}.$$
(5)

Let the initial conditions of (3)–(4) be the equilibrium point (X^*, P^*) (5). In this 3 case we say that the pair formation process is at equilibrium. This assumption im-4 plies that X' = 0 and P' = 0, so the total population size is constant with $N = \nu/\mu$. 5 Thus, assuming equilibrium of the pair formation process we may reduce model (1) 6 to the following three-dimensional system: 7 --1

$$X_{1}' = (\sigma + \mu)I - (2\mu + \rho + \sigma)X_{1} - (\gamma + u_{T})X_{1},$$

$$P_{01}' = \rho \left(1 - h(1 - u_{C})\right)X_{1} \left(1 - \frac{X_{1}}{X^{*}}\right) - (\sigma + \phi h(1 - u_{C}) + 2\mu)P_{01}$$

$$+ (\gamma + u_{T})\left(I - X_{1} - 2P_{01}\right),$$

$$I' = \rho h(1 - u_{C})X_{1} \left(1 - \frac{X_{1}}{X^{*}}\right) + \phi h(1 - u_{C})P_{01} - \mu I - (\gamma + u_{T})I,$$
(6)

where $I = X_1 + P_{01} + 2P_{11}$ is the total prevalence.

2.2 Basic Reproduction Number 10

In this section we analyze the reduced pair model (6) assuming that the control 11

functions $u \in \{u_T, u_C\}$ are constant functions over time. Suppose that the control 12

functions are given by $u_T(t) = u_T^0$ and $u_C(t) = u_C^0$ for all time t, where u_T^0 and u_C^0 13 are fixed constants that satisfy condition (2). Then, system (6) turns into: 14

$$\begin{aligned} X_1' &= (\sigma + \mu)I - (2\mu + \rho + \sigma)X_1 - (\gamma + u_T^0)X_1, \\ P_{01}' &= \rho(1 - h(1 - u_C^0))X_1 \left(1 - \frac{X_1}{X^*}\right) - (\sigma + \phi h(1 - u_C^0) + 2\mu)P_{01} \\ &+ (\gamma + u_T^0)(I - X_1 - 2P_{01}), \\ I' &= \rho h(1 - u_C^0)X_1 \left(1 - \frac{X_1}{X^*}\right) + \phi h(1 - u_C^0)P_{01} - \mu I - (\gamma + u_T^0)I. \end{aligned}$$
(7)

The basic reproduction number \mathcal{R}_0 for pair models is defined as the expected 16 number of secondary infections one typical infectious individual will produce dur-17 ing his/her infectious period, starting in a P_{11} partnership within a completely sus-18 ceptible population (see Heijne et al., 2013). Thus, the basic reproduction number 19 associated to model (7) is 1 : 20

 $\mathcal{R}_{0} = \frac{h(1-u_{C}^{0})\left[\rho(\sigma+\mu)(\sigma+2(\gamma+u_{T}^{0})+2\mu+\phi)+(\gamma+u_{T}^{0})\phi(\gamma+u_{T}^{0}+\mu+\rho)\right]}{(\mu+\gamma+u_{T}^{0})(\sigma+\phi h(1-u_{C}^{0})+2\mu+2(\gamma+u_{T}^{0}))(2\mu+\rho+\sigma+\gamma+u_{T}^{0})}$ (8) 21

2

¹ For details on the computation of \mathcal{R}_0 see Saldaña and Barradas (2019).

A triplet (X_1^*, P_{01}^*, I^*) is called an endemic equilibrium point of model (7) if $I^* > 0$ and if the triplet satisfies the following non-linear system:

$$X_1^* = \frac{(\sigma + \mu)I^*}{2\mu + \rho + \sigma + (\gamma + u_T^0)},$$
(9)

$$P_{01}^{*} = \frac{\rho(1 - h(1 - u_{C}^{0}))X_{1}^{*}}{\sigma + \phi h(1 - u_{C}^{0}) + 2\mu + 2(\gamma + u_{T}^{0})} \left(1 - \frac{X_{1}^{*}}{X^{*}}\right)$$
$$(\gamma + u_{T}^{0})(I^{*} - X_{1}^{*})$$
(10)

$$+\frac{(\gamma + u_T)(1 - u_T)}{\sigma + \phi h(1 - u_C^0) + 2\mu + 2(\gamma + u_T^0)},$$
(10)

$$I^* = \frac{\rho h (1 - u_C^0) X_1^*}{\mu + (\gamma + u_T^0)} \left(1 - \frac{X_1^*}{X^*} \right) + \frac{\phi h (1 - u_C^0) P_{01}^*}{\mu + (\gamma + u_T^0)}.$$
 (11)

System (9)–(11) comes from setting the left-hand side of (7) equal to zero. Assume that (X_1^*, P_{01}^*, I^*) is an endemic equilibrium point. From (9) we can see that $I^* > X_1^* > 0$. In addition, given that $X_1^* \le X^*$, from equation (10) we deduce that $I^* > P_{01}^* > 0$. In summary, if (X_1^*, P_{01}^*, I^*) is an endemic equilibrium point then

$$I^* > 0, \quad I^* > X_1^* > 0, \quad I^* > P_{01}^* > 0.$$

Substituting the values of X_1^* and P_{01}^* in equation (11) and solving for I^* , we get:

$$I^* = (\mathcal{R}_0 - 1) \frac{(\mu + \gamma + u_T^0)(\sigma + \phi h(1 - u_C^0) + 2\mu + 2(\gamma + u_T^0))(2\mu + \rho + \sigma + \gamma + u_T^0)^2 X^*}{\rho h(1 - u_C^0)(\sigma + 2(\gamma + u_T^0) + 2\mu + \phi)(\sigma + \mu)^2}.$$
(12)

³ This, in turn, can be used to explicitly determine the values of X_1 and P_{01} at the ⁴ endemic equilibrium. Moreover, when $\mathcal{R}_0 > 1$ all the factors on the right-hand ⁵ side of expression (12) are positive. Therefore, $I^* > 0$ exists if and only if $\mathcal{R}_0 > 1$. ⁶ The following result summarizes the role of the basic reproduction number in the ⁷ dynamics of the disease.

Theorem 1 For the constant controls model (7), the disease-free equilibrium $E_0 = (0, 0, 0)$ always exists and it is locally asymptotically stable if and only if $\mathcal{R}_0 < 1$. For $\mathcal{R}_0 > 1$, the vector $E_1 = (X_1^*, P_{01}^*, I^*)$, where X_1^*, P_{01}^* and I^* are given by the solution of system (9)–(11), is the only endemic equilibrium point of model (7) and it is locally asymptotically stable.

Proof It is straightforward to see that $E_0 = (0, 0, 0)$ is the disease-free equilibrium for model (7). To investigate the local stability of the equilibrium points, we compute the Jacobian matrix of the model (7):

$$J(X_1, P_{01}, I) = \begin{pmatrix} J_{11} & 0 & \sigma + \mu \\ J_{21} & J_{22} & \gamma + u_T^0 \\ J_{31} & \phi h(1 - u_C^0) - (\mu + \gamma + u_T^0) \end{pmatrix}$$

where:

$$J_{11} = 2\mu + \rho + \sigma - (\gamma + u_T^0), \quad J_{21} = \rho(1 - h(1 - u_C^0)) \left(1 - \frac{2X_1}{X^*}\right) - (\gamma + u_T^0),$$

$$J_{22} = -(\sigma + \phi h(1 - u_C^0) + 2\mu + 2(\gamma + u_T^0)), \quad J_{31} = \rho h(1 - u_C^0) \left(1 - \frac{2X_1}{X^*}\right).$$




Fig. 2: Contour plots for \mathcal{R}_0 with respect to constant controls u_T^0 and u_C^0 . Model parameter values are found in Table 4.

The characteristic polynomial for the Jacobian matrix evaluated at the disease-free equilibrium $J(E_0)$ is $P_1(\lambda) = \lambda^3 + a_2\lambda^2 + a_1\lambda + a_0(1 - \mathcal{R}_0)$ where:

$$\begin{aligned} a_2 &= 2\sigma + 4(\gamma + u_T^0) + 5\mu + \rho + h(1 - u_C^0)\phi, \\ a_1 &= (\sigma + 2(\gamma + u_T^0) + 2\mu + h(1 - u_C^0)\phi)(\sigma + (\gamma + u_T^0) + 2\mu + \rho) \\ &+ ((\gamma + u_T^0) + \mu)(2\sigma + 3(\gamma + u_T^0) + 4\mu + \rho + h(1 - u_C^0)\phi), \\ &- h(1 - u_C^0)(\rho(\sigma + \mu) + (\gamma + u_T^0)\phi), \\ a_0 &= (\sigma + 2(\gamma + u_T^0) + 2\mu + h(1 - u_C^0)\phi)((\gamma + u_T^0) + \mu)(\sigma + (\gamma + u_T^0) + 2\mu + \rho). \end{aligned}$$

Note that coefficients a_i are positive for i = 0, 1, 2. Thus, $P_1(\lambda)$ is an strictly in-

² creasing function for $\lambda \in \mathbb{R}^+$. Furthermore, $P_1(0) > 0$ if and only if $\mathcal{R}_0 < 1$.

³ In consequence, if $\mathcal{R}_0 < 1$, then the roots of the polynomial $P_1(\lambda)$ have negative

⁴ real part. However, $P_1(\lambda)$ has a unique positive real root if $\mathcal{R}_0 > 1$. Therefore, the

⁵ disease-free equilibrium is locally asymptotically stable if $\mathcal{R}_0 < 1$, and it is unstable ⁶ if $\mathcal{R}_0 > 1$.

We have already established that for $\mathcal{R}_0 > 1$ the point $E_1 = (X_1^*, P_{01}^*, I^*)$ is the only endemic equilibrium for model (7). The characteristic polynomial for the Jacobian matrix evaluated at the endemic equilibrium $J(E_1)$ is $P_2(\lambda) = \lambda^3 + b_2\lambda^2 + b_1\lambda + b_0(\mathcal{R}_0 - 1)$ where

$$b_2 = a_2 > 0$$
, $b_1 = a_1 + h(1 - u_C^0)\rho(\sigma + \mu)\left(\frac{2X_1^*}{X^*}\right) > 0$, $b_0 = a_0 > 0$.

Seeing that $P_2(0) > 0$ if $\mathcal{R}_0 > 1$, and that $P_2(\lambda)$ is an increasing function of λ when $\lambda > 0$, we obtain the local asymptotic stability of E_1 .

To illustrate the behavior of the basic reproduction number (8) with respect to parameter perturbations, we show a contour plot for \mathcal{R}_0 in which we vary the values of u_T^0 and u_C^0 (Figure 2). The numerical values of the model parameters come from two case studies –chlamydia and gonorrhea– that are introduced later in Section 4. We observe in Figure 2 that increasing u_C^0 have stronger effects than increasing u_T^0 towards reducing \mathcal{R}_0 . See Supplementary Material, S1 where bifurcation diagrams with respect to u_T^0 and u_C^0 are shown.

1 3 Optimal Control Problem

6

² The theoretical results from the previous section allow us to predict qualitative be-

havior of non-constant control strategies. In this section our objective is to model
 optimization of resources used by the control strategies. In order to do that, we

5 propose the following objective functional

$$J(u_T, u_C) = \int_0^{t_f} I(t) + B_T u_T(t)^2 + B_C u_C(t)^2 dt$$
(13)

 $_{7}$ for a fixed final time t_{f} . This objective functional has the aim of penalizing the

 $_{8}$ presence of infected individuals, as well as the use of the control functions u_{T}

 ${}_{9}$ ${}_{and}$ $u_{C}.$ The quadratic terms penalize high control levels in comparison with low

values of the control functions (Gaff and Schaefer, 2009). The weight parameters

¹¹ B_T and B_C in (13) balance the impact of the presence of infected people and the ¹² use of control. The value of *J* depends exclusively on *I*, if B = 0; whereas, for large

values of *B*, *J* is heavily affected by the use of the control, for $B \in \{B_T, B_C\}$.

We define the set of admissible controls, $D(t_f)$, as the set of Lebesgue measurable functions u_T , u_C that satisfy conditions (2) for all time $t \in [0, t_f]$. Thus, the general optimal control problem is:

$$\min_{u_T, u_C \in D(t_f)} J(u_T, u_C) \text{ subject to system (6).}$$
(14)

The existence of solutions to the optimal control problem may be proved through standard analytical results. In Appendix B, details are provided for solution existence to the simplified only-treatment model ($u_C \equiv 0$) but similar arguments are valid to the general optimal control problem (14).

Next, we obtain the so-called optimality system in order to find a numerical approximation of optimal control employing the Forward-Backward Sweep Method

20 (see Lenhart and Workman, 2007, Chapter 4). This system corresponds to comple-

²¹ menting the reduced model (6) with an adjoint dual system. The optimality system

²² is completed by a characterization of the optimal control solutions in terms of the

²³ state and the adjoint variables.

24 3.1 Optimality System

Theorem 2 Consider the optimal control problem (14). Given an optimal control vector $(u_T^{\dagger}, u_C^{\dagger})$ and its corresponding state variables X_1^{\dagger} , P_{01}^{\dagger} and I^{\dagger} , there exist three adjoint variables $\lambda_1(t)$, $\lambda_2(t)$ and $\lambda_3(t)$ that satisfy the system:

$$\begin{split} u_{T}^{\dagger} &= \min\left\{M_{T}, \max\left\{0, \frac{X_{1}^{\dagger}\lambda_{1} + \lambda_{2}(2P_{01}^{\dagger} - I^{\dagger} + X_{1}^{\dagger}) + \lambda_{3}I^{\dagger}}{2B_{T}}\right\}\right\},\\ u_{C}^{\dagger} &= \min\left\{M_{C}, \max\left\{0, \frac{\lambda_{2}\left(X_{1}^{\dagger}h\rho\left(\frac{X_{1}^{\dagger}}{X^{*}} - 1\right) - P_{01}^{\dagger}h\phi\right) + \lambda_{3}\left(X_{1}^{\dagger}h\rho\left(\frac{X_{1}^{\dagger}}{X^{*}} - 1\right) - P_{01}^{\dagger}h\phi\right)}{2B_{C}}\right\}\right\},\\ X_{1}^{\dagger'} &= (\sigma + \mu)I^{\dagger} - (2\mu + \rho + \sigma)X_{1}^{\dagger} - (\gamma + u_{T}^{\dagger})X_{1}^{\dagger},\\ P_{01}^{\dagger'} &= \rho\left(1 - h(1 - u_{C}^{\dagger})\right)X_{1}^{\dagger}\left(1 - \frac{X_{1}^{\dagger}}{X^{*}}\right) - \left(\sigma + \phi h(1 - u_{C}^{\dagger}) + 2\mu\right)P_{01}^{\dagger} \end{split}$$

$$+ (\gamma + u_T^{\dagger})(I^{\dagger} - X_1^{\dagger} - 2P_{01}^{\dagger}),$$

$$I^{\dagger'} = \rho h(1 - u_C^{\dagger})X_1^{\dagger} \left(1 - \frac{X_1^{\dagger}}{X^*}\right) + \phi h(1 - u_C^{\dagger})P_{01}^{\dagger} - \mu I^{\dagger} - (\gamma + u_T^{\dagger})I^{\dagger},$$

$$\lambda'_1 = \left(2\mu + \rho + \sigma + \gamma + u_T^{\dagger}\right)\lambda_1 + \left(\gamma + u_T^{\dagger} - \rho\left(1 - h(1 - u_C^{\dagger})\right)\left(1 - \frac{2X_1^{\dagger}}{X^*}\right)\right)\lambda_2$$

$$- h(1 - u_C^{\dagger})\rho\left(1 - \frac{2X_1^{\dagger}}{X^*}\right)\lambda_3,$$

$$\lambda'_2 = \left(2\mu + \sigma + 2(\gamma + u_T^{\dagger}) + h(1 - u_C^{\dagger})\phi\right)\lambda_2 - h(1 - u_C^{\dagger})\phi\lambda_3,$$

$$\lambda'_3 = -(\mu + \sigma)\lambda_1 - (\gamma + u_T^{\dagger})\lambda_2 + \left(\mu + \gamma + u_T^{\dagger}\right)\lambda_3 - 1,$$

$$X_1^{\dagger}(0), P_{01}^{\dagger}(0), I^{\dagger}(0) \text{ given, } \lambda_1(t_f) = \lambda_2(t_f) = \lambda(t_f) = 0.$$

$$(15)$$

Proof Let *H* be the Hamiltonian function defined by:

$$\begin{split} H = &\lambda_1 \left((\sigma + \mu)I - (2\mu + \rho + \sigma)X_1 - (\gamma + u_T)X_1 \right) \\ &+ \lambda_2 \left(\rho(1 - h)X_1 \left(1 - \frac{X_1}{X^*} \right) - (\sigma + \phi h + 2\mu)P_{01} + (\gamma + u_T)(I - X_1 - 2P_{01}) \right) \\ &+ \lambda_3 \left(\rho hX_1 \left(1 - \frac{X_1}{X^*} \right) + \phi hP_{01} - \mu I - (\gamma + u_T)I \right) + B_T u_T^2 + I. \end{split}$$

Using the Pontryagin's Maximum Principle (Pontryagin et al., 1965), we get that the following system is satisfied at the optimal control vector $(u_T^{\dagger}, u_C^{\dagger})$:

$$\begin{split} \lambda_1 &= -\frac{\partial H}{\partial X_1}, \quad \lambda_2 = -\frac{\partial H}{\partial P_{01}}, \quad \lambda_3 = -\frac{\partial H}{\partial I}, \quad \lambda_i(t_f) = 0 \quad (i = 1, 2, 3), \\ \frac{\partial H}{\partial u_T}\Big|_{u_T = u_T^{\dagger}} &= 0, \quad \frac{\partial H}{\partial u_C}\Big|_{u_C = u_C^{\dagger}} = 0, \end{split}$$

from which the system (15) is derived. \Box

Similar results may be obtained for $u_C \equiv 0$ (only-treatment control is employed) and for $u_T \equiv 0$ (only-condom promotion control is employed). The corresponding optimality systems for these two models can be found in Appendices C and D.

5 4 Numerical Results

6 In this section we explore model (6) numerically using trichomoniasis, gonorrhea, 7 chlamydia and HPV as case studies. We retrieved from the literature **numerical** 8 estimates for some parameters related to the transmission of these four infections. 9 Parameter values are shown in Tables 3–4. We aim to model an adverse scenario in 10 which a high level of infected population is prevalent. Thus, we consider I(0) =11 7×10^5 where half of this population comes from the total of susceptible-infected 12 pairs ($P_{01}(0) = 3 \times 10^5$). We considered the final time to be $t_f = 20$ years as in 13 Malik et al. (2016). We analyze the dynamics model (6) for three different families of control func-

² tions. The first one is a permanent control program (constant control). The second

³ one is a control program that increases efforts accordingly to higher infected popu-

- ⁴ lation levels (feedback control). Finally, the third one is a control strategy that aims
- 5 to minimize the overall cost (optimal control).

6 4.1 Case Studies

7 Curable STIs: Trichomoniasis, gonorrhea, and chlamydia

In Figures 3–5 the simulations related to the four STIs considered in this work can
be found. The left-hand column plots show the corresponding constant, feedback
and optimal controls for each of these STIs, and the right-hand plots show the resulting prevalence dynamics. The three curable STIs considered (trichomoniasis,
gonorrhea, and chlamydia) are studied under the effect of both proposed control

¹³ strategies: the treatment control u_T and the condom promotion control u_C .

14 Non-curable STI: HPV infection

15 As mentioned in the introduction, HPV infection remains as a non-curable STI.

¹⁶ Therefore, we only considered the effect of the condom promotion u_C for this dis-

¹⁷ ease. At the bottom of Figure 4 we show HPV infection control via condom promo-

18 tion control.

19 4.2 Control Strategies

20 Constant

In practice, a constant control function $u(t) = u^0$ for all time t may not be appropriate. This is because it does not take into account important factors such as the evolution of the prevalence level. Nevertheless, it is useful to predict the global dynamics of model (1) gaining some insight into how other types of control strategies may perform. For the numerical simulations, we employed two constant values that will correspond to the maximum values attainable by the optimal and feedback controls. We considered $u_T^0 = M_T = 1.0$ years $^{-1}$ corresponding to the treatment control, and $u_C^0 = M_C = 0.75$ (dimensionless) for the condom promotion control.

29 On the left-hand side of Figures 3 and 4 the control functions for the different

³⁰ STIs are shown. In Figures 3 and 4, the constant control strategies allow us to predict

- the best hypothetical scenario where the maximum decrease of the prevalence level
- ³² is attained.

33 Feedback

- ³⁴ In a more realistic scenario, public health authorities may take decisions on how
- ³⁵ to control an STI based on the current prevalence at a certain time. In that case, a
- ³⁶ convenient control strategy is one that only depends on the burden of the infected

Parameter	Value	Source
$X_1(0)$	1×10^{5}	Assumed
$P_{01}(0)$	3×10^5	Assumed
I(0)	7×10^5	Assumed
N	1×10^{6}	Assumed
ρ	5.0	Heijne et al. (2011)
σ	2.0	Heijne et al. (2011)
μ	0.111	Johnson et al. (2001)
ν	1.111×10^{5}	$N\mu = \nu$
ϕ	52.0	Johnson et al. (2001)

Table 3: Population and sexual behavior parameter values.

Disease	γ	h	Source
Trichomoniasis	0.727	0.115	Johnson and Geffen (2016)
Gonorrhea	1.538	0.348	Johnson and Geffen (2016)
Chlamydia	0.855	0.129	Johnson and Geffen (2016)
HPV	0.5	0.073	Juckett and Hartman-Adams (2010)

Table 4: Sexual transmitted infection parameter values.

- population. These strategies use fewer control efforts when prevalence achieves ac-
- ² ceptable levels, whereas it uses maximum efforts when such prevalence is above a
- ³ critical level. We propose the control function

$$u(t) = \Phi(I(t)) = \frac{M}{1 + \exp\{-k[I(t) - I_{alert}]\}},$$
(16)

for $t \in [0, t_f]$, where $I_{alert} > 0$ represents an alert level at which a maximum con-5 trol reaction speed k is reached, and $u \in \{u_T, u_C\}$ with respective $M \in \{M_T, M_C\}$. 6 This is a standard sigmoid function that saturates at M. We incorporated this feed-7 back control u into model (1) following a previous work (Saldaña and Barradas, 8 2019). Here we employed the following parameters for the feedback function (16): 9 $I_{alert} = 1 \times 10^5$ that corresponds to 10% of the total population, and $k = 1 \times 10^{-4}$. 10 Note that although is not always possible to obtain prevalence data, the World 11 Health Organization periodically estimates the global and regional prevalence of 12 some common sexually transmitted diseases including chlamydia, trichomoniasis 13 and gonorrhea (WHO, 2012b; Newman et al., 2015). Therefore, it is realistic to con-14 sider feedback control based on I(t). 15 In Figures 3 and 4 the feedback controls are also shown on the left-hand side. 16

Note that in all cases the feedback controls begins at its highest possible value $M \in \{M_T, M_C\}$ and then drift to a constant lower value. The lower value is positive since the objective of the feedback control is to act if the prevalence is above the

20 alert level.

21 Optimal

²² The optimal control solutions were obtained by solving the optimization problems

²³ mentioned in Section 3. We obtained solution approximations to the optimality sys-

²⁴ tems by using the Forward-Backward Sweep Method (see Lenhart and Workman,

- $_{25}$ 2007, Chapter 4). For the numerical simulations we used the following weight pa-
- rameters: $B_T = B_C = 5 \times 10^5$. These values were chosen as a way to compensate
- ²⁷ for the magnitude of the prevalence level.




Fig. 3: Only-treatment control strategy ($u_C \equiv 0$) applied to the three curable STIs. Three types of control are considered: constant, feedback, and optimal controls. The final time is $t_f = 20$ years.

In Figures 3–5 the optimal controls are also present. Note that for the case of the 1 only-treatment model (Figure 3) the optimal control solutions behave in a linear-2 like manner from the highest value M_T until they reach zero. On the other hand, 3 in the only-condom promotion model (Figure 4) the optimal control solutions have 4 a defined period of time where they have the highest value M_C . Then, there is an 5 intermediate period of time where they drop quickly, and finally, there is a period of 6 linear-like behavior. In Figure 5 we tested the simultaneous optimal control strate-7 gies and found out that the treatment control has defined convex behavior. In terms 8 of prevalence control, the mixed strategies model (Figure 5) have a better perfor-9 mance than the other two models (Figures 3 and 4). 10




Fig. 4: Only-condom promotion control strategy ($u_T \equiv 0$) applied to the four STIs. Three types of control are considered: constant, feedback, and optimal controls.




Fig. 5: Treatment and condom promotion optimal control strategies applied simultaneously to the three curable STIs.

1 4.3 Cost-Effectiveness Analysis

² To compare different types of control structures (constant, feedback, and optimal

controls), we need to define two quantities of interest: the cost of a strategy, and
 the number of averted individuals by a strategy. Here, we use a cost functional
 given by:

$$Cost(u_T, u_C) = \int_0^{t_f} B_T u_T(t)^2 + B_C u_C(t)^2 + A_1 I(t) u_T(t) + A_2 \phi P_{01}(t) u_C(t) dt,$$
 (17)

7 and also an averted functional given by:

8

$$Averted(u_T, u_C) = \int_0^{t_f} I_0(t) - I_{\dagger}(t)dt, \qquad (18)$$

⁹ where I_0 is the prevalence level under no control, whereas I_{\dagger} is the prevalence ¹⁰ level under control functions u_T and u_C .

It is noteworthy to mention that many works in the literature refer to ob-1 jective functional for finding optimal control solutions also as a cost functional, 2 see for instance Okosun et al. (2011); Rodrigues et al. (2014a); Agusto and ELmoз jtaba (2017) and Nandi et al. (2018). There are few works that employ different objective and cost functionals; for instance, in Sepulveda and Vasilieva (2016); Berhe et al. (2018) and Tilahun et al. (2018), the cost functional is regarded as the objective functional without the terms with no control variables, which only considers inherent control costs. Here, we also make a difference between objective 8 functionals for optimal controls and cost functionals for general strategies. In 9 an attempt to make a fair comparison between optimal control and non-optimal 10 control strategies, we pay attention to the subsequent economic cost that a strat-11 egy generates based on the number of individuals affected; similar approaches 12 may be found in Rodrigues et al. (2014b); Otieno et al. (2016) and Momoh and 13 Fügenschuh (2018). Therefore, we want to emphasize that the optimal control so-14 lutions that we find satisfy an objective functional (13) that penalizes high levels 15 of control, whereas a cost functional (17) is proposed to incorporate economic 16 17 cost of applying the control strategies in their respective population compartments. Moreover, in the cost functional (17), the terms whose coefficients are A_1 18 and $A_2 - A_1 I u_T$ and $A_2 \phi P_{01} u_C$ - measure the frequency of control application, 19 that is, the costs of treating Iu_T individuals per year and of condom use among 20 $P_{01}u_C$ susceptible-infected pairs per year, respectively. 21

We evaluated the cost-effectiveness of the control strategies for each STI using 22 the increased cost-effectivity ratio (ICER) (Okosun et al., 2011; Cape et al., 2013): 23

$$ICER(f) = \frac{Cost(f)}{Averted(f)}, \quad ICER(f,g) = \frac{Cost(f) - Cost(g)}{Averted(f) - Averted(g)}, \tag{19}$$

where f and g are assumed to be strategies conformed by pairs of functions u_T and 25

 u_C , while Cost and Averted are the functionals defined by (17) and (18), respec-26

tively. Observe from equation (19) that for individual strategies, it is more desir-27

able to have ICER(f) small: low cost and high averted levels. For two strategies, 28 ICER(f, g) compares the cost-effectivity of the second strategy g with respect the

29 first strategy f. The standard method to determine the most cost-effective strategy 30

is as follows: 31

- 1. The strategies to be compared are sorted from lowest to highest costs. 32
- 2. The ICER for the first strategy, and the ICER between the first and second strate-33 gies are computed using (19). 34
- 3. If the ICER between the two strategies is negative, eliminate the second strategy: 35 the second strategy has higher cost and lower averted levels. 36
- 37
- 4. Assume that the ICER between the two strategies is positive.
- If the first strategy has a lower ICER than the ICER between the two strate-38 gies, then eliminate the second strategy: the second strategy has higher a-39
- verted levels but it is proportionally lower than the first strategy. 40
- Otherwise, eliminate the first strategy: the second strategy has higher averted 41 levels proportionally with respect to the first strategy. 42
- 5. Repeat the process until only one strategy remains in the list. 43

trichomoniasis								
A1=0	A2=0							
	cost	averted	ICER			cost	averted	ICER
OT optimal	2.64E+006	5.05E+007	0.05			Ļ		
OT feedback	2.85E+006	4.99E+007	-0.31		OT optimal	2.64E+006	5.05E+007	0.05
OC optimal	3.23E+006	4.97E+007			mixed	3.58E+006	6.21E+007	0.08
OC feedback	3.25E+006	4.64E+007			OC constant	5.63E+006	5.35E+007	
mixed	3.58E+006	6.21E+007			OT constant	1.00E+007	5.83E+007	
OC constant	5.63E+006	5.35E+007				Ļ		
OT constant	1.00E+007	5.83E+007			OT optimal	2.64E+006	5.05E+007	0.05
	\downarrow				OC constant	5.63E+006	5.35E+007	1.00
OT optimal	2.64E+006	5.05E+007	0.05		OT constant	1.00E+007	5.83E+007	
OC optimal	3.23E+006	4.97E+007	-0.73			Ļ		
OC feedback	3.25E+006	4.64E+007			OT optimal	2.64E+006	5.05E+007	0.05
mixed	3.58E+006	6.21E+007			OT constant	1.00E+007	5.83E+007	0.95
OC constant	5.63E+006	5.35E+007				+		
OT constant	1.00E+007	5.83E+007			OT optimal	2.64E+006	5.05E+007	0.05
	+							
OT optimal	2.64E+006	5.05E+007	0.05					
OC feedback	3.25E+006	4.64E+007	-0.15					
mixed	3.58E+006	6.21E+007						
OC constant	5.63E+006	5.35E+007						
OT constant	1.00E+007	5.83E+007						

Table 5: ICER-based cost-effectiveness determination process for trichomoniasis. 'OT': only-treatment, 'OC': only-condom promotion, 'mixed': mixed strategy optimal control.




Table 6: ICER-based cost-effectiveness analysis. For each STI and for each pair of parameters (A_1, A_2) with values (0, 0), (10, 1) and (100, 10), we show the corresponding most cost-effective strategy. 'OT': only-treatment, 'OC': only-condom promotion, 'mixed': mixed strategy optimal control.

As an illustrative example, in Table 5, we gathered the results of the ICER-1 based cost-effectiveness analysis for trichomoniasis. The same process was per-2 formed to the other three STIs, and computations may be found in Supplemen-3 tary Material, S2. In Table 6, we show the most cost-effective strategies for each **STI** while varying the weight parameters (A_1, A_2) . We observe in Table 6 that the cost-effectiveness varied among the four STIs considered. When the values 6 of A_1 and A_2 were low, optimal controls had the highest cost-effectiveness. For the cases of trichomoniasis and chlamydia, only-treatment optimal control and 8 mixed strategy optimal control had the highest cost-effectivenesses. For the case 9 of gonorrhea, only-condom optimal control and mixed strategy optimal control 10 had the highest cost-effectivenesses. On the other hand, when A_1 and A_2 were 11 high, constant controls u_T^0 and u_C^0 showed the highest cost-effectivenesses for tri-12 chomoniasis and HPV infection, while mixed strategy optimal control displayed 13 the highest cost-effectivenesses for chlamydia and gonorrhea. 14

15 5 Discussions and Conclusions

In this work, we proposed an extension of a pair model (Kretzschmar and Dietz, 16 1998; Saldaña and Barradas, 2019) to explore STI control under public health strate-17 gies. Three different control structures were studied: constant control, feedback con-18 trol, and optimal control. Constant controls are useful to predict the prevalence evo-19 lution through theoretical results, such as the computation of the basic reproduc-20 tion number \mathcal{R}_0 . Feedback controls reflect public health strategies that depend on 21 the prevalence levels. Finally, optimal controls are designed to minimize the preva-22 lence levels and the use of the control strategy through time. Here, we characterized 23 optimal solutions using Pontryagin's Maximum Principle and obtained numerical 24 approximations via the Forward-Backward Sweep Method. For the numerical sim-25 ulations, and because of being four of the most common and problematic STIs, 26 we used parameters related to trichomoniasis, gonorrhea, chlamydia and HPV in-27 fections. We employed the ICER methodology as a way to contrast the cost-effec-28 tiveness of the different strategies considered in this work. We emphasize that our 29 purpose here was to investigate the control of STIs in the form of treatment and 30 condom promotion for pair models with monogamous partnerships. 31 Cost-effectiveness analysis compares the costs and health outcomes of alter-32 native strategies. The health gains can be measured using some pertinent health 33 outcome, such as the total number of infections averted. On the other hand, the 34 cost might include direct healthcare costs (e.g. pharmaceutical costs, hospitaliza-35 tion, etc.) and non-healthcare costs (e.g. administrative costs, patient time cost, 36 etc.). The measurement and the evaluation of these resources are not straight-37 forward. Therefore, defining mathematical criteria to compare different types of 38 control is a challenging task. Here, we proposed the cost functional (17) and, con-39 sidering the lack of additional empirical data, analyzed different scenarios for 40 its weight factors. Our results point out that, when only inherent control cost is 41 considered, optimal control solutions are the most cost-effective strategies. How-42 ever, when the cost of applying such controls on the population is considered, 43 constant controls may arise as the most cost-effective strategies because they de-44

⁴⁵ crease considerably the number of infected individuals.

As shown in this work, the impact of health public strategies on controlling STI

² prevalence may be predicted, and improved based on different criteria such as the

³ practicality of implementation (feedback control) or the minimization of an objec-

- ⁴ tive functional (optimal control). This work is the first attempt to use optimal con-
- ⁵ trol to search for the most efficient way to develop public health strategies for STIs
- considering the pair formation process , and also the first one to shown quantita tively the effects of varying cost functional parameters on the cost-effectiveness
- 8 analysis.

⁹ As future work, concurrency (overlapping of partnerships), sexual risk groups,

or studying the relationship between the infectious disease and the pair formation
 process can be included. HPV infection remains as a non-curable STI, but it could

process can be included. HPV infection remains as a non-curable STI, but it could
 be interesting to include vaccination in the pair model. Also, it could be appropriate

¹³ to consider a different way to measure the strategies cost.

14 Acknowledgements We appreciate the invaluable feedback from the anonymous reviewers that

improved this work. AC and FS acknowledge Mexico CONACyT for the Graduate Fellowship Grants 412803 and 331194, respectively. This work was partially supported by Mexico CONACyT

¹⁷ Project CB2016-286437. Finally, we also express our gratitude to Dr. Janet Mary Izzo for revising the

19 Code availability The Matlab and Python codes used to run the simulations in this work may be

20 found in https://github.com/arielcam27/STIs_pairModel_control

21 Supplementary material

22 Appendix A. Positively invariant sets

Consider the pair model (1):

$$\begin{split} X_0' &= \nu + (\sigma + \mu)(2P_{00} + P_{01}) - (\mu + \rho)X_0 + (\gamma + u_T)X_1, \\ X_1' &= (\sigma + \mu)(2P_{11} + P_{01}) - (\mu + \rho)X_1 - (\gamma + u_T)X_1, \\ P_{00}' &= \frac{1}{2}\rho\frac{X_0^2}{X} - (\sigma + 2\mu)P_{00} + (\gamma + u_T)P_{01}, \\ P_{01}' &= \rho\left(1 - h(1 - u_C)\right)\frac{X_0X_1}{X} - (\sigma + \phi h(1 - u_C) + 2\mu)P_{01} \\ &- (\gamma + u_T)P_{01} + 2(\gamma + u_T)P_{11}, \\ P_{11}' &= \frac{1}{2}\rho\frac{X_1^2}{X} + \rho h(1 - u_C)\frac{X_0X_1}{X} + \phi h(1 - u_C)P_{01} - (\sigma + 2\mu)P_{11} \\ &- 2(\gamma + u_T)P_{11}. \end{split}$$

- By adding the equations, note that the total population size $N = X_0 + X_1 + 2(P_{00} + P_{01} + P_{11})$
- satisfies $\bar{N}' = -\mu N + \nu$, and thus

$$N(t) \le N(0)e^{-\mu t} + \frac{\nu}{\mu} \left(1 - e^{-\mu t}\right).$$
⁽²⁰⁾

If we consider the set

$$\Omega = \{ (X_0, X_1, P_{00}, P_{01}, P_{11}) \in \mathbb{R}^5_+ \mid X_0 + X_1 + 2(P_{00} + P_{01} + P_{11}) \le \nu/\mu \}$$

- then, from (20), we get that if $N(0) \in \Omega$ then $N(t) \in \Omega$ for all t > 0. We say that Ω is a positively
- 27 invariant set under (1).

¹⁸ manuscript.

Appendix B. Existence of solutions to the optimal control problem

- To prove existence of solutions for the only-treatment optimal control problem, we use Theorem
 4.1 and Corollary 4.1 from Fleming and Rishel (1975, Chapter III, Section 4). Such result requires
- 4 the following:

16

- 5 1. The set of solutions of the system (6) (called admissible pairs) is not empty.
- 6 2. The set of admissible controls, i.e. functions *u* satisfying the control conditions (2), is closed and convex.
- B 3. The right-hand side of the system (6) is continuous, bounded from above by a sum of the states
 and the control, and it can be written as a linear function of the control.
- 4. Finally, the integrand of (13) is convex in the control, and it is bounded below by $c_1|u|^g c_2$ with $c_1 > 0$ and g > 1.
- We can see that $u_T \equiv 0$ is an admissible solution, so the set of admissible pairs is not empty. Since $u_T \in D(t_f)$ (see Section 3 to recall the definition of the set D) then the set of admissible
- controls is closed and convex. Note that the supersolutions of (6), which we are going to denote by \hat{X}_1 , \hat{P}_{01} and \hat{I} , satisfy the following ODE system:
 - $\widehat{X_1}' = (\sigma + \mu)\widehat{I},$ $\widehat{P_{01}}' = \rho \widehat{X_1} + M\widehat{I},$

$$\widehat{I}' = \rho \widehat{X}_1 + M \widehat{I},$$

$$\widehat{I}' = \rho \widehat{X}_1 + \phi \widehat{P}_{01},$$
(21)

which is a linear system. Thus, the solutions of system (21) are uniformly bounded for any finite time interval $[0, t_f]$. Let us define

$$f(X_1, P_{01}, I) = \begin{pmatrix} (\sigma + \mu)I - (2\mu + \rho + \sigma)X_1 - (\gamma + u_T)X_1 \\ \rho(1 - h)X_1 \left(1 - \frac{X_1}{X^*}\right) - (\sigma + \phi h + 2\mu)P_{01} + (\gamma + u_T)(I - X_1 - 2P_{01}) \\ \rho hX_1 \left(1 - \frac{X_1}{X^*}\right) + \phi hP_{01} - \mu I - (\gamma + u_T)I \end{pmatrix}.$$

It is straightforward to note that there exists a function $g(X_1, P_{01}, I)$ such that

21
$$f(X_1, P_{01}, I) = g(X_1, P_{01}, I) + u_T \begin{pmatrix} -X_1 \\ I - X_1 - 2P_{01} \\ -I \end{pmatrix}$$

and so the right-hand side of (6) can be written as a linear function of u_T . Also, we already have satisfied the continuity of the model. Finally, using the supersolutions system (21) we note that

$$\|f(X_1, P_{01}, I)\| \le \left\| \begin{pmatrix} 0 & 0 & \sigma + \mu \\ \rho & 0 & M \\ \rho & \phi & P_{01} \end{pmatrix} \begin{pmatrix} X_1 \\ P_{01} \\ I \end{pmatrix} + u_T \begin{pmatrix} -X_1 \\ I - X_1 - 2P_{01} \\ -I \end{pmatrix} \right\| \le C \left(\|(X_1, P_{01}, I)\| + \|u_T\| \right)$$

- where C is a constant that depends on the model parameters. Thus, f is bounded from above by a
- sum of the states and the control. The integrand is $\hat{h}(I, u_T) = I + Bu_T^2$ and so $h(I, u) = I + Bu_T^2 \ge Bu_T^2$, so choosing $c_2 = 0$, $c_1 = B > 0$ and g = 2 we have the following:
- **Theorem 3** There exist an optimal control u_T and state variables (X_1, P_{01}, I) that minimize the objective function I(2) and state variables (X_1, P_{01}, I) that minimize the objective
- $_{26}$ functional (13) and satisfy the system (6). \Box

27 Appendix C. Optimality system for the only-treatment model

²⁸ The corresponding optimality system for the only-treatment control strategy ($u_C \equiv 0$) is given by:

$$u_T = \min\left\{M_T, \max\left\{0, \frac{X_1\lambda_1 + \lambda_2(2P_{01} - I + X_1) + \lambda_3I}{2B_T}\right\}\right\},\label{eq:uT}$$

$$\begin{split} X_1' &= (\sigma + \mu)I - (2\mu + \rho + \sigma)X_1 - (\gamma + u_T)X_1, \\ P_{01}' &= \rho(1 - h)X_1 \left(1 - \frac{X_1}{X^*}\right) - (\sigma + \phi h + 2\mu)P_{01} + (\gamma + u_T)(I - X_1 - 2P_{01}), \\ I' &= \rho hX_1 \left(1 - \frac{X_1}{X^*}\right) + \phi hP_{01} - \mu I - (\gamma + u_T)I, \\ \lambda_1' &= (2\mu + \rho + \sigma + \gamma + u_T)\lambda_1 + \left(\gamma + u_T - \rho(1 - h)\left(1 - \frac{2X_1}{X^*}\right)\right)\lambda_2 - h\rho\left(1 - \frac{2X_1}{X^*}\right)\lambda_3, \\ \lambda_2' &= (2\mu + \sigma + 2(\gamma + u_T) + h\phi)\lambda_2 - h\phi\lambda_3, \\ \lambda_3' &= -(\mu + \sigma)\lambda_1 - (\gamma + u_T)\lambda_2 + (\mu + \gamma + u_T)\lambda_3 - 1, \\ X_1(0), P_{01}(0), I(0) \text{ given, } \lambda_1(t_f) = \lambda_2(t_f) = \lambda(t_f) = 0. \end{split}$$

² Appendix D. Optimality system for the only-condom promotion model

³ The corresponding optimality system for the only-condom promotion control strategy ($u_T \equiv 0$) is ⁴ given by:

$$\begin{split} u_C &= \min\left\{ M_C, \max\left\{ 0, \frac{\lambda_2 \left(X_1 h \rho \left(\frac{X_1}{X^*} - 1 \right) - P_{01} h \phi \right) + \lambda_3 \left(X_1 h \rho \left(\frac{X_1}{X^*} - 1 \right) - P_{01} h \phi \right)}{2B_C} \right\} \right\}, \\ X_1' &= (\sigma + \mu)I - (2\mu + \rho + \sigma)X_1 - \gamma X_1, \\ P_{01}' &= \rho \left(1 - h(1 - u_C) \right) X_1 \left(1 - \frac{X_1}{X^*} \right) - (\sigma + \phi h(1 - u_C) + 2\mu) P_{01} + \gamma (I - X_1 - 2P_{01}), \\ I' &= \rho h(1 - u_C)X_1 \left(1 - \frac{X_1}{X^*} \right) + \phi h(1 - u_C)P_{01} - \mu I - \gamma I, \\ \lambda_1' &= (2\mu + \rho + \sigma + \gamma) \lambda_1 + \left(\gamma - \rho \left(1 - h(1 - u_C) \right) \left(1 - \frac{2X_1}{X^*} \right) \right) \lambda_2 \\ &- h(1 - u_C)\rho \left(1 - \frac{2X_1}{X^*} \right) \lambda_3, \\ \lambda_2' &= (2\mu + \sigma + 2\gamma + h(1 - u_C)\phi) \lambda_2 - h(1 - u_C)\phi\lambda_3, \\ \lambda_3' &= -(\mu + \sigma) \lambda_1 - \gamma \lambda_2 + (\mu + \gamma) \lambda_3 - 1, \\ X_1(0), P_{01}(0), I(0) \text{ given, } \lambda_1(t_f) &= \lambda_2(t_f) = \lambda(t_f) = 0. \end{split}$$

5 References

- Agusto FB, ELmojtaba IM (2017) Optimal control and cost-effective analysis of malaria/vis ceral leishmaniasis co-infection. PLOS ONE, 12(2), e0171102. https://doi.org/10.1371/
 journal.pone.0171102
- Berhe HW, Makinde OD, Theuri DM (2018) Optimal Control and Cost-Effectiveness Analysis
 for Dysentery Epidemic Model. Appl Math Inf Sci, 12(6), 1183-1195. https://doi.org/10.
- 11 18576/amis/120613
- Brauer F, Castillo-Chavez C (2012) Mathematical models in population biology and epidemiology.
 New York: Springer
- Camacho A, Jerez Š (2019) Bone metastasis treatment modeling via optimal control. J Math Bio, 78(1-2), 497-526. https://doi.org/10.1007/s00285-018-1281-3
- 16 Cape JD, Beca JM, Hoch JS (2013) Introduction to cost-effectiveness analysis for clinicians. University of Toronto Medical Journal, 90(3)

CDC (2013) of sexually transmitted infections Incidence, prevalence, and cost 1 United States. Retrieved from 2 in the http://www.cdc.gov/std/stats/ sti-estimates-fact-sheet-feb-2013.pdf 3 Fleming WH, Rishel RW (1975) Deterministic and Stochastic Optimal Control. Springer-Verlag 4 Gaff H, Schaefer E (2009) Optimal control applied to vaccination and treatment strategies for var-5 ious epidemiological models. Math Biosci Eng, 6(3), 469-492. https://doi.org/10.3934/ 6 009.6.40 mhe ' Gerbase AC, Rowley JT, Mertens TE (1998) Global epidemiology of sexually transmitted diseases. 8 Lancet, 351, S2-S4. https://doi.org/10.1016/ 736 (98) 90001-0 B Gumel A, MS Lubuma J, Sharomi O, Terefe YA (2018) Mathematics of a sexstructured model 10 for syphilis transmission dynamics. Math Methods Appl Sci, 41(18), 8488-8513. https://doi. 11 0.1002/mma.4734 12 Heijne JC, Althaus CL, Herzog SA, Kretzschmar M, Low N (2011) The role of reinfection and part-13 ner notification in the efficacy of Chlamydia screening programs. J Infect Dis, 203(3), 372-377. 14 https://doi.org/10.1093/infdis/jiq050 15 16 Heijne JC, Herzog SA, Althaus CL, Low N, Kretzschmar M (2013) Case and partnership reproduction numbers for a curable sexually transmitted infection. J Theor Biol, 331, 38-47. https: 17 j.jtbi.2013.04 18 /doi.org/10.1016/ Johnson AM, Mercer CH, Erens B, Copas AJ, McManus S, Wellings K, ..., Purdon, S (2001) Sexual 19 behaviour in Britain: partnerships, practices, and HIV risk behaviours. Lancet, 358(9296), 1835-20 1842. https:/ org/10.1016/S0140-6736(01)06883 21 Johnson LF, Geffen N (2016) A Comparison of Two Mathematical Modeling Frameworks for Eval-22 uating Sexually Transmitted Infection Epidemiology. Sex Transm Dis, 43(3), 139-146. https: 23 000000000000041 24 org/10.1097/010 Juckett G, Hartman-Adams H (2010) Human papillomavirus: clinical manifestations and preven-25 tion. Am Fam Physician, 82(10), 1209-1213 26 27 Kretzschmar M, Dietz K (1998) The effect of pair formation and variable infectivity on the spread of an infection without recovery. Math Biosci, 148(1), 83-113. https://doi.org/10.1016/ 28 S0025-5564 (97) 10008 29 Kretzschmar M, Heijne JC (2017) Pair formation models for sexually transmitted infections: A 30 primer. Infect Dis Model, 2(3), 368-378. https://doi.org/10.1016/j.idm.2017.07.002 31 Lenhart S, Workman JT (2007) Optimal control applied to biological models. CRC Press 32 Malik T, Imran M, Jayaraman R (2016) Optimal control with multiple human papillomavirus vac-33 cines. J Theor Biol, 393, 179-193. https://doi.org/10.1016/ .jtbi 16.01.00 34 Milwid RM, Frascoli F, Steben M, Heffernan JM (2018) HPV Screening and Vaccination Strategies 35 in an Unscreened Population: A Mathematical Modeling Study. Bull Math Biol, 1-30. https: 36 //doi.org/10.1007/s11538-018-0425 37 Momoh AA, Fügenschuh A (2018) Optimal control of intervention strategies and cost effectiveness 38 analysis for a Zika virus model. Oper Res Health Care, 18, 99-111. https://doi.org/10. 39 1016/j.orhc.2017.08.004 40 Muller H, Bauch C (2010) When do sexual partnerships need to be accounted for in transmission 41 models of human papillomavirus? Int J Environ Res Public Health, 7(2), 635-650. https:// 42 doi.org/10.3390 43 Nandi SK, Jana S, Mandal M, Kar TK (2018) Mathematical Analysis of an Epidemic System in the 44 Presence of Optimal Control and Population Dispersal. Biophys Rev Lett, 13(01), 1-17. https: 45 46 /doi.or Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, ..., Temmerman M 47 (2015) Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmit-48 ted Infections in 2012 Based on Systematic Review and Global Reporting. PLoS ONE, 10(12), 49 e0143304.https 50 /doi.org/ .1371/journal.pone.01433 Okosun KO, Ouifki R, Marcus N (2011) Optimal control analysis of a malaria disease transmission 51 model that includes treatment and vaccination with waning immunity. Biosystems, 106(2-3), 52 136-145. https://doi.org/10.1016/j.biosystems.2011.07.00 53 Otieno G, Koske J, Mutiso J (2016) Cost Effectiveness Analysis of Optimal Malaria Control Strate-54 gies in Kenya. Mathematics, 4(1), 14. https://doi.org/10.3390/math402 55 Owusu-Edusei Jr K, Chesson HW, Gift TL, Tao G, Mahajan R, Ocfemia MCB, Kent CK (2013) The es-56 timated direct medical cost of selected sexually transmitted infections in the United States, 2008. 57 Sex Transm Dis, 40(3), 197-201. https://doi org/10.1097/OLO.0b013e318285c6 58 Pontryagin LS, Boltyanskii VG, Gamkrelidze RV, Mishchenko EF (1965) The Mathematical Theory 59 of Optimal Processes. Interscience 60

- 1 Rodrigues HS, Monteiro MTT, Torres DFM (2014) Vaccination models and optimal control strategies to dengue. Math Biosci, 247, 1-12. https://doi.org/10.1016/j.mbs.2013.10.006
- Rodrigues P, Silva CJ, Torres DFM (2014) Cost-Effectiveness Analysis of Optimal Control Measures for Tuberculosis. Bull Math Biol, 76(10), 2627-2645. https://doi.org/10.1007/
- s11538-014-0028-6
 Saldaña F, Barradas I (2019) The role of behavioral changes and prompt treatment in the control of
- STIs. Infect Dis Model, 4, 1-10. https://doi.org/10.1016/j.idm.2018.12.001
 Sepulveda LS, Vasilieva O (2016) Optimal control approach to dengue reduction and prevention in
- Sepulveda LS, Vasilieva O (2016) Optimal control approach to dengue reduction and prevention in
 Cali, Colombia. Math Meth Appl Sci, 39(18), 5475-5496. https://doi.org/10.1002/mma.
 3932
- 11
 Sharomi O, Malik T (2017) Optimal control in epidemiology. Ann Oper Res, 251(1-2), 55-71. https:

 12
 //doi.org/10.1007/s10479-015-1834-4
- Tilahun, G. T., Makinde, O. D., and Malonza, D. (2018) Co-dynamics of Pneumonia and Typhoid
 fever diseases with cost effective optimal control analysis. Appl. Math.Comput, 316, 438-459.
 https://doi.org/10.1016/j.amc.2017.07.063
- Unemo M, Bradshaw CS, Hocking JS, de Vries HJ, Francis SC, Mabey D, ..., Peeling RW (2017)
 Sexually transmitted infections: challenges ahead. Lancet Infect Dis, 17(8), e235-e279. https:
 //doi.org/10.1016/S1473-3099(17) 30310-9

¹⁹ Villavicencio Pulido G, Barradas I, Luna B (2017) Backward bifurcation for some general recovery

- functions. Math Methods Appl Sci, 40(5), 1505-1515. https://doi.org/10.1002/mma.4074
 Wang W (2006) Backward bifurcation of an epidemic model with treatment. Math Biosci, 201(1-2),
- 22 58-71. https://doi.org/10.1016/j.mbs.2005.12.022
- World Health Organization (2012b) Global incidence and prevalence of selected curable sexually
 transmitted infections-2008. Geneva: World Health Organization

25 Zhang X, Liu X (2008) Backward bifurcation of an epidemic model with saturated treatment func-

tion. J Math Anal Appl, 348(1), 433-443. https://doi.org/10.1016/j.jmaa.2008.07. 042